SpringWorks Therapeutics Inc
NASDAQ:SWTX
SpringWorks Therapeutics Inc
Interest Income Expense
SpringWorks Therapeutics Inc
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
SpringWorks Therapeutics Inc
NASDAQ:SWTX
|
Interest Income Expense
$20m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$2.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$970m
|
CAGR 3-Years
16%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-9%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$3.3B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-18%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$558m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
124%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$773.4m
|
CAGR 3-Years
33%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
SpringWorks Therapeutics Inc
Glance View
SpringWorks Therapeutics Inc., a cutting-edge biopharmaceutical company, emerged from its inception as a strategic spin-out venture from the global pharmaceutical giant Pfizer. Born in 2017, the company cleverly positions itself at the forefront of the drug development process, with a keen focus on targeting rare diseases and cancer. SpringWorks leverages its robust pipeline of therapies, specifically designed to address significant unmet medical needs. Their approach revolves around the repurposing and reinvigoration of underappreciated and overlooked clinical molecules, which previously lacked the necessary backing to reach the market. This innovative approach allows SpringWorks to harness upstream R&D efforts while minimizing the typical time and resources required for de novo drug development. Earning its stripes in the field, SpringWorks generates revenue primarily through milestone and royalty agreements tied to its partnerships and co-development collaborations. Rather than relying solely on traditional sales of approved drugs, the company emphasizes strategic alliances with research institutions and pharmaceutical partners to advance its drug candidates. This co-development model extends its reach and augments the company's research capabilities, enabling SpringWorks to share risks and tap into broader resources. By nurturing innovations through collaboration, SpringWorks not only enriches its pipeline but also stands as a vanguard in transforming potential therapies into commercial realities, ultimately positioning itself as a linchpin in the orphan disease market.
See Also
What is SpringWorks Therapeutics Inc's Interest Income Expense?
Interest Income Expense
20m
USD
Based on the financial report for Dec 31, 2024, SpringWorks Therapeutics Inc's Interest Income Expense amounts to 20m USD.
What is SpringWorks Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
85%
Over the last year, the Interest Income Expense growth was 12%.
You don't have any saved screeners yet